PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Herold, T. ; Metzeler, K.H. ; Vosberg, S. ; Hartmann, L. ; Röllig, C.* ; Stölzel, F.* ; Schneider, S.* ; Hubmann, M. ; Zellmeier, E.* ; Ksienzyk, B.* ; Jurinovic, V.* ; Pasalic, Z.* ; Kakadia, P.M.* ; Dufour, A.* ; Graf, A.* ; Krebs, S.* ; Blum, H.* ; Sauerland, M.C.* ; Büchner, T.* ; Berdel, W.E.* ; Woermann, B.J.* ; Bornhäuser, M.* ; Ehninger, G.* ; Mansmann, U.* ; Hiddemann, W. ; Bohlander, S.K.* ; Spiekermann, K. ; Greif, P.A.

Isolated trisomy 13 defines a genetically homogenous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis.

Blood 124, 1304-1311 (2014)
Publ. Version/Full Text DOI PMC
Closed
Open Access Green as soon as Postprint is submitted to ZB.
Isolated trisomy 13 (AML+13) is a rare chromosomal abnormality in acute myeloid leukemia (AML), and its prognostic relevance is poorly characterized. We analyzed the clinical course of 34 AML+13 patients enrolled in the German AMLCG-1999 and SAL trials and studied their biological characteristics by exome sequencing, targeted sequencing of candidate genes and gene expression profiling. Relapse-free (RFS) and overall survival (OS) of AML+13 patients were inferior compared to other ELN Intermediate-II patients (n=855) (median RFS, 7.8 vs 14.1 months, p=0.006; median OS 9.3 vs. 14.8 months, p=0.004). Besides the known high frequency of RUNX1 mutations (75%), we identified mutations in spliceosome components in 88%, including SRSF2 codon 95 mutations in 81%, of AML+13 patients. Moreover, recurring mutations were detected in ASXL1 (44%) and BCOR (25%). Two patients carried mutations in CEBPZ, suggesting that CEBPZ is a novel recurrently mutated gene in AML. Gene expression analysis revealed a homogenous expression profile including upregulation of FOXO1 and FLT3 and downregulation of SPRY2. This is the most comprehensive clinical and biological characterization of AML+13 to date, and reveals a striking clustering of lesions in a few genes, defining AML+13 as a genetically homogenous leukemia subgroup with alterations in a few critical cellular pathways. These studies were registered at clinicaltrials.gov, identifiers: AMLCG-1999: NCT00266136; AML96: NCT00180115; AML2003: NCT00180102; and AML60+: NCT00893373.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
9.775
2.425
52
58
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Acute Myeloid-leukemia; Chronic Lymphocytic-leukemia; Increased Flt3 Expression; European Leukemianet; Down-regulation; Cancer; Recommendations; Consolidation; Mitoxantrone; Abnormality
Language english
Publication Year 2014
HGF-reported in Year 2014
ISSN (print) / ISBN 0006-4971
e-ISSN 1528-0020
Journal Blood
Quellenangaben Volume: 124, Issue: 8, Pages: 1304-1311 Article Number: , Supplement: ,
Publisher American Society of Hematology
Publishing Place Washington
Reviewing status Peer reviewed
Institute(s) CCG Pathogenesis of Acute Myeloid Leukemia (KKG-KPL)
POF-Topic(s) 30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
Research field(s) Immune Response and Infection
PSP Element(s) G-521000-001
PubMed ID 24923295
DOI 10.1182/blood-2013-12-540716
WOS ID WOS:000342761900023
Scopus ID 84907303242
Erfassungsdatum 2014-06-15
[➜Report correction]